Literature DB >> 20507766

Original antigenic sin and pandemic (H1N1) 2009.

Amesh A Adalja, D A Henderson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20507766      PMCID: PMC3086248          DOI: 10.3201/eid1606.091653

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: While pandemic (H1N1) 2009 was in its earliest stages, age distribution data indicated surprisingly few cases among persons >65 years of age. The initial assumption was that few persons >65 years of age had yet to be exposed. However, as more data became available from Mexico, Australia, and the United States, the age distribution pattern persisted (). This observation raised the question about whether older persons were protected from infection with an influenza virus A (H1N1) strain acquired many years ago. Indeed, data from the Centers for Disease Control and Prevention showed that approximately two thirds of older persons have evidence of immunity to pandemic (H1N1) 2009 virus. In 1960, Thomas Francis proposed the hypothesis of original antigenic sin, a phenomenon whereby a person who as a child was first exposed to a specific influenza virus A would, throughout life, mount an immune response to the virus of childhood, even when exposed to other antigenically dissimilar influenza viruses. In effect, the original antibody response generated by the immune system against a specific influenza viral strain was hypothesized to have colored all future responses to influenza (). Serologic responses of humans and other mammals have supported this theory. A new hemagglutinin (HA) subtype emerged in 1918 that was responsible for the pandemic that year. Through 1956, the strain evolved, accumulating mutations. In an era before influenza viruses were subtyped was performed, the original 1918 influenza virus A (H1N1) was dubbed a swine strain, whereas the virus of the 1930s was known as influenza A. However, the amount of drift accrued by 1947 was enough to render the seasonal vaccine of the time ineffective, and the new drifted virus strain was named A′. Throughout the period, the virus continued to be the subtype H1N1, as it is now designated. In 1956, Davenport and Hennessy examined the antibody responses of 3 different age cohorts, each of which received different monovalent influenza vaccines prepared with vaccine strains circulating at different earlier periods () (Table). Prevaccination serum samples confirmed the presence of antibodies specific to the influenza virus that circulated during each respective cohort’s childhood.
Table

Influenza strains dominant for specific age cohorts from 1956 study*

Age cohort, yInfluenza strain
4–10 (born 1946–1952)A′
17–28 (born 1928–1939)A
>30 (born <1926)Swine

*Adapted from ().

*Adapted from (). Each of the 3 monovalent vaccines was administered to a group from each age cohort. Vaccination directed toward influenza strains distinct from the virus of childhood not only resulted in development of immunity to the vaccine strain but also boosted the immune response to the virus strain that circulated during each person’s childhood, i.e., original antigenic sin was apparent in each age cohort. Several other studies with humans, ferrets, rats, and rabbits yielded similar results (,5). Evidence from more recent studies largely supported the veracity of original antigenic sin. In a 1976 study, persons were vaccinated with a virus that circulated in 1973, an antigenically drifted variant of the 1968 influenza virus A (H3N2), and the response was assessed. As in earlier studies, examination of the antibodies generated indicated that the vaccine-induced antibodies were not only to the 1973 variant it contained but also to the virus that had circulated earlier. As the hypothesis postulates, the vaccine-induced antibodies to the 1968 strain were more numerous than those to the actual vaccine strain (). Results from a 1984 experiment that used cell cultures with donor lymphocytes were similar (). A 1994 study found that current vaccine strains induced antibodies to the influenza virus circulating during the childhood of persons in each age cohort (). An additional study, published in 2009, confirmed the presence of antigenic sin in mice and showed a greater tendency for live-virus vaccines to produce the phenomenon (). One recent study is at variance with the others. It showed that monoclonal antibodies generated through vaccination were highly specific to the current vaccine strain rather than to influenza strains that had circulated in the past (). At the advent of the 2009 pandemic, fears of a severe pandemic were rampant. However, any prior immunity that was present in the population would dampen the impact of the virus. Early reports confirmed that the virus was less common in groups of older adults. Vaccine recommendations for certain age groups were developed according to that pattern of illness. Because influenza virus A (H1N1) circulated continually after 1918 until 1957, most persons born before 1957 had been infected primarily with subtype H1N1. According to the theory of original antigenic sin, these persons may have partial protection from severe disease from infection with the new influenza virus A (H1N1), i.e., pandemic (H1N1) 2009. Supporting this hypothesis is the paucity of infections in Mexico from persons now in their 50s and 60s and few reports in the United States or Australia of cases in this age group (). This fact should inform policy decisions and merits further immunologic consideration. Influenza surge planning is premised on a high incidence of illness among elderly persons, but if the current pattern of illness continues, healthcare facilities also should prepare to treat younger persons who may constitute the bulk of cases. Additionally, studies of persons born during 1957–1968
should be conducted to quantify antibody levels to pandemic (H1N1) 2009 virus, focusing on the degree of preexisting immunity that may have existed and was boosted by prior encounters with subtype H1N1 viruses
  9 in total

1.  Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin".

Authors:  D C Powers; R B Belshe
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

2.  Specificity of in vitro anti-influenza virus antibody production by human lymphocytes: analysis of original antigenic sin by limiting dilution cultures.

Authors:  R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

3.  Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-05-08       Impact factor: 17.586

4.  Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans.

Authors:  R G Webster; J A Kasel; R B Couch; W G Laver
Journal:  J Infect Dis       Date:  1976-07       Impact factor: 5.226

5.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

6.  Original antigenic sin responses to influenza viruses.

Authors:  Jin Hyang Kim; Ioanna Skountzou; Richard Compans; Joshy Jacob
Journal:  J Immunol       Date:  2009-07-31       Impact factor: 5.422

7.  Disquisitions on Original Antigenic Sin. II. Proof in lower creatures.

Authors:  R G Webster
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

8.  A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine.

Authors:  F M DAVENPORT; A V HENNESSY
Journal:  J Exp Med       Date:  1956-07-01       Impact factor: 14.307

9.  Disquisitions of Original Antigenic Sin. I. Evidence in man.

Authors:  R G Webster
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

  9 in total
  12 in total

1.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy.

Authors:  Suresh Pallikkuth; Sudheesh Pilakka Kanthikeel; Sandra Y Silva; Margaret Fischl; Rajendra Pahwa; Savita Pahwa
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

3.  The 2009 H1N1 pandemic influenza virus: what next?

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  MBio       Date:  2010-09-28       Impact factor: 7.867

4.  Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus.

Authors:  Christopher D O'Donnell; Amber Wright; Leatrice Vogel; Kobporn Boonnak; John J Treanor; Kanta Subbarao
Journal:  Clin Vaccine Immunol       Date:  2014-03-19

5.  Searching for sharp drops in the incidence of pandemic A/H1N1 influenza by single year of age.

Authors:  Jessica Hartman Jacobs; Brett Nicholas Archer; Michael G Baker; Benjamin J Cowling; Richard T Heffernan; Geoff Mercer; Osvaldo Uez; Wanna Hanshaoworakul; Cécile Viboud; Joel Schwartz; Eric Tchetgen Tchetgen; Marc Lipsitch
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

6.  The wages of original antigenic sin.

Authors:  David M Morens; Donald S Burke; Scott B Halstead
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

7.  Phylogenetic evidence for a mild H1 pandemic in the early 1900s.

Authors:  Steven Riley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

8.  Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus.

Authors:  Michael Worobey; Guan-Zhu Han; Andrew Rambaut
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

9.  Characterization of immune responses induced by immunization with the HA DNA vaccines of two antigenically distinctive H5N1 HPAIV isolates.

Authors:  Yulong Gao; Zhiyuan Wen; Ke Dong; Gongxun Zhong; Xiaomei Wang; Zhigao Bu; Hualan Chen; Ling Ye; Chinglai Yang
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

10.  Determinants of individuals' risks to 2009 pandemic influenza virus infection at household level amongst Djibouti city residents--a CoPanFlu cross-sectional study.

Authors:  Fred Andayi; Pascal Crepey; Alexia Kieffer; Nicolas Salez; Ammar A Abdo; Fabrice Carrat; Antoine Flahault; Xavier de Lamballerie
Journal:  Virol J       Date:  2014-01-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.